Our conclusion is that there do not appear to have been any major clinically important differences in effects on hypoglycemia, hyperglycemia, weight or long-term safety between the three available RAIs among insulin-naive individuals with type 2 diabetes who were monitored for up to 6.4 years in clinical practice. This evidence concerns the gene INS and type 2 diabetes mellitus.